Allergy and Immunology, Allergy · Omaha, NE
NPI
1295884526
Since 2007
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
16945 Frances St
Omaha, NE, 68130
Phone (402) 397-7400
Groups this clinician bills Medicare through
Medicare paid, 2024
$277K
11,944 services
Medicare patients, 2024
234
Average age 73
Drug cost, 2024
$2.1M
1,317 prescriptions
Company payments, 2025
$2,505
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaine Brownell was code J2182 (injection, mepolizumab, 1 mg), 5,701 times for 13 patients. In total Jaine Brownell billed 11,944 services in 32 codes, and Medicare paid $277K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2182 Injection, mepolizumab, 1 mg | Office | 5,701 | 13 | $23.82 | $136K |
| J2357 Injection, omalizumab, 5 mg | Office | 2,490 | 15 | $29.95 | $75K |
| 95004 Test - Miscellaneous | Office | 1,785 | 47 | $2.37 | $4,236 |
| 96372 Injection Administration | Office | 146 | 38 | $10.47 | $1,529 |
| 99214 Office E&M - Established | Office | 113 | 91 | $80.74 | $9,124 |
| 95115 Treatment - Miscellaneous | Office | 106 | 30 | $5.89 | $624 |
| 94010 Pulmonary Function Testing | Office | 90 | 72 | $17.21 | $1,549 |
| 95165 Treatment - Miscellaneous | Office | 75 | 11 | $8.35 | $626 |
| 95117 Treatment - Miscellaneous | Office | 48 | 19 | $7.96 | $382 |
| 99204 Office E&M - New | Office | 48 | 48 | $101.85 | $4,889 |
| 99213 Office E&M - Established | Office | 34 | 32 | $50.52 | $1,718 |
| 94060 Pulmonary Function Testing | Office | 20 | 20 | $25.32 | $506 |
| 99203 Office E&M - New | Office | 17 | 17 | $63.72 | $1,083 |
By year: 2022 $235K for 10,329 services; 2023 $282K for 11,924 services; 2024 $277K for 11,944 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jaine Brownell prescribed most often to Medicare patients was Montelukast Sodium, with 199 prescriptions and refills. In total Jaine Brownell wrote 1,317 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 199 | 401 | 38 | $1,357 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 156 | 189 | 28 | $112K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 92 | 114 | 40 | $2,198 |
| Fluticasone Propionate Generic | 88 | 157 | 30 | $1,215 |
| Azelastine Hcl Generic | 70 | 111 | 27 | $2,044 |
| Ipratropium Bromide Generic | 60 | 94 | 18 | $2,689 |
| Symbicort Budesonide/Formoterol Fumarate | 47 | 58 | Under 11 | $12K |
| Breo Ellipta Fluticasone/Vilanterol | 43 | 59 | Under 11 | $21K |
| Dupixent Syringe Dupilumab | 39 | 39 | Under 11 | $150K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 35 | 45 | 11 | $9,232 |
| Arnuity Ellipta Fluticasone Furoate | 29 | 47 | Under 11 | $9,059 |
| Azithromycin Generic | 25 | 25 | Under 11 | $384 |
| Omeprazole Generic | 25 | 33 | Under 11 | $376 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 23 | 40 | Under 11 | $2,956 |
| Triamcinolone Acetonide Generic | 23 | 30 | Under 11 | $275 |
Brand drugs: 544 claims; generic drugs: 773 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaine Brownell $2,505 ($2,505 in general payments such as food, travel and fees) from 25 companies. The largest payer was Genzyme Corporation with $612.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 28 | $612 |
| CSL Behring CSL.AX | 10 | $171 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $170 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $158 |
| GlaxoSmithKline, LLC. GSK | 13 | $148 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $133 |
| Genentech USA, Inc. ROG.SW | 5 | $127 |
| Pfizer Inc. PFE | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $100 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $94.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.